A Study of SHR-1210± SHR-1020 Versus Chemotherapy in Patients With Recurrent or Metastatic Cervical Cancer

NCT04680988 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

194

Enrollment

INDUSTRY

Sponsor class

Conditions

Recurrent or Metastatic Cervical Cancer

Interventions

DRUG: SHR-1210
DRUG: SHR-1020
DRUG: Physician's choice chemotherapy

Sponsor

Jiangsu HengRui Medicine Co., Ltd.